What is GLP-1? A Plain-English Guide

The Short Version

GLP-1 stands for glucagon-like peptide-1 — a 30-amino-acid hormone secreted by L-cells in the small intestine. It was identified in the 1980s as an "incretin": a gut hormone that amplifies insulin secretion in response to food.

For most of medical history, GLP-1 was studied as a diabetes drug. The discovery that it also powerfully suppresses appetite and slows gastric emptying turned it into the most-prescribed weight loss treatment in history.

What GLP-1 Does in Your Body

After a meal, GLP-1 levels rise and trigger a cascade:

1. Pancreas — stimulates insulin release proportional to blood glucose (reducing the risk of hypoglycemia)
2. Hypothalamus — activates satiety centers, reducing hunger signals
3. Stomach — slows gastric emptying so you feel full longer
4. Liver — suppresses glucagon, preventing the liver from dumping excess glucose

The net effect: you eat less, absorb nutrients more slowly, and feel satisfied on fewer calories.

Natural GLP-1 vs. GLP-1 Medications

Your body's own GLP-1 has a half-life of roughly 2 minutes — it's degraded almost immediately by the enzyme DPP-4. That's why natural GLP-1 release doesn't produce dramatic weight loss on its own.

GLP-1 receptor agonist medications (semaglutide, tirzepatide, liraglutide) are engineered analogs that resist DPP-4 breakdown. Weekly injectable semaglutide (Ozempic, Wegovy) has a half-life of about 7 days — maintaining consistently elevated GLP-1 signaling that the natural hormone never achieves.

Why GLP-1 Medications Produce So Much Weight Loss

The STEP 1 trial (Wilding et al., NEJM, 2021) found weekly semaglutide 2.4 mg produced a mean 14.9% reduction in body weight over 68 weeks — roughly 34 lbs for a 225 lb person. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) found tirzepatide produced up to 20.9% body weight reduction over 72 weeks.

These results were unprecedented for a pharmaceutical intervention. The mechanism goes beyond appetite suppression: GLP-1 medications also reduce food reward, alter food preferences (particularly toward high-fat foods), and may directly affect fat metabolism.

Who Is GLP-1 For?

Current FDA-approved indications vary by drug:

• Ozempic (semaglutide 0.5–2 mg) — Type 2 diabetes
• Wegovy (semaglutide 2.4 mg) — Obesity (BMI ≥30 or ≥27 with weight-related condition)
• Mounjaro (tirzepatide 5–15 mg) — Type 2 diabetes
• Zepbound (tirzepatide 5–15 mg) — Obesity

Off-label prescribing is common. Eligibility criteria and insurance coverage vary significantly.

Bottom Line

GLP-1 medications work by maintaining the satiety and metabolic signals your gut hormone naturally produces — but at sustained, pharmacologic levels your body can't achieve on its own. The clinical evidence is clear: they produce more weight loss than any previously available medication, and the science behind how they work is well-established.

This article is for informational purposes only. Always consult a licensed healthcare provider before starting GLP-1 therapy.

Sources

• Wilding JPH et al., "Once-Weekly Semaglutide in Adults with Overweight or Obesity," NEJM, 2021
• Jastreboff AM et al., "Tirzepatide Once Weekly for the Treatment of Obesity," NEJM, 2022
• Drucker DJ, "The biology of incretin hormones," Cell Metabolism, 2006